anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a natural skin whitening soap and a production method thereof. Animal pancreas and soybean meal are taken as main raw materials, Vc extracts from kiwi fruit, strawberry and lemon are added, and white sugar, talcum powder, flavouring, pigments and the like are matched. The invention also relates to ingredients and the production method of the natural skin whitening soap. The following raw materials are adopted in percentage by weight: 20-40% of animal pancreas, 40-50% of soybean meal, 20% of Vc (extracts of kiwi fruit, strawberry and lemon), 0.1-0.5% of white sugar, 3-5% of talcum powder, 0.1-0.3% of spice and 0.2-0.6% of pigments. Kiwi fruit, strawberry and lemon are peeled and flesh of kiwi fruit, strawberry and lemon are placed into a glass container to be ground into slurry by a homogenizer, and then slurry is filtered. Benzene or methylbenzene is added for extraction, sodium permanganate is used for oxidation, and then hydrolysis, esterification, transformation and neutralization are carried to obtain Vc, animal pancreas and soybeans are grounded in container; and the ground animal pancreas and soybeans are mixed with the talcum powder, and moulding and drying are carried out, thus the natural skin whitening soap is obtained. The natural skin whitening soap provided by the invention can whiten and improve skin, can minimize pores and has no stimulation, toxic or side effect.
Polyostotic fibrous dysplasia (PFD) is a sporadic disorder which affects multiple sites in the skeleton. The bone at these sites is rapidly resorbed and replaced by abnormal fibrous tissue. PFD may occur alone or as part of the McCune-Albright Syndrome (MAS), a syndrome originally defined by the triad of PFD, cafe au lait pigmentation of the skin, and precocious puberty. The bony lesions are frequently disfiguring and painful. In addition, depending on the location of the lesion, they can cause significant morbidity. Lesions in weight-bearing bones can lead to disabling fractures, while lesions in the skull can lead to compression of vital structures such as the cranial nerves.

Currently there are no clearly-defined systemic or local therapies for the bone disease, and results of the use of conventional surgical treatment of sites of impending fracture have been universally disappointing. In this study, we will treat osteolytic lesions in the long bones of the upper and lower extremities, the sites of potential fracture, with a novel surgical approach. This will involve 1) the removal of abnormal tissue through percutaneous aspiration, and 2) the use of skeletal precursor cells taken from the unaffected sites, mixed with a bone grafting substitute, and injected into the affected sites to bring about an improvement in local bone quality and overall patient function.
The invention discloses a raidx astragali particle. The radix astragali particle is prepared by a following method: the medicinal materials of the radix astragali are decocted with water and extracted twice; the medicinal materials of the radix astragali are decocted for 1.5 to 2.5hours every time; decoctions are put together and filtered;  filtrate is concentrated into a clear paste with relative density of 1.20 to 1.30 (70 to 80 DEG C); auxiliary materials are added and mixed evenly; then the medicinal materials of the radix astragali and the auxiliary materials are processed by granulation, drying, sub-package and sterilization; and the raidx astragali particle is made. The radix astragali particle is prepared by the new method and the procedures of alcohol precipitation is reduced. That decoction time is changed is beneficial to the dissolution and preservation of effective components. As a result, the effective components of the medicinal materials of the radix astragali, including astragalus polysaccharides and total saponin, and the like, are reserved in the radix astragali particle as much as possible, thus greatly improving the content of the effective components so as to improve the clinical effectiveness of the raidx astragali. Meanwhile, production period is greatly shortened; energy consumption is decreased; and cost is lowered. The invention also provides a quality control method of the raidx astragali particle.
All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
Osteoarthritis (OA) is a chronic disease due to the deterioration of cartilage structure and function, involving the progressive degradation of the cartilage extracellular matrix. Cathepsins, lysosomal cysteine proteases, play pivotal roles in various biological and pathological processes, particularly in protein degradation. Excess cathepsins levels are reported to contribute to the development of OA. However, the causal relationship between the cathepsin family and knee and hip OA remains uncertain. Therefore, this study utilized bidirectional Mendelian Randomization (MR) analyses to explore this causal association. Our results indicated that elevated serum levels of cathepsin O increase the overall risk of knee OA, while increased serum levels of cathepsin H enhance the risk of hip OA. Conversely, the reverse MR analyses did not reveal a reverse causal relationship between them. In summary, OA in different anatomical locations may genetically result from pathological elevations in different serum cathepsin isoforms, which could be utilized as diagnostic and therapeutic targets in clinical practice.
The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.
The present invention relates to a compound anticarcinogen slow-released injection containing vasoinhibitor and its synergist. It is composed of slow-released microsphere and solvent. The slow-released microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is general solvent or special solvent containing suspension adjuvant. The anticancer effective component is combination of vasoinhibitor and vasoinhibitor synergist of antitumor antibiotic or antimetabolite medicine, the slow-released auxiliary material is one selected from racemic polylactic acid and its copolymer, monomethyl polyethylene glycol and polylactic acid copolymer, polyethylene glycol and polylactic acid copolymer, carboxyl terminated polylactic acid and glycollic acid copolymer and ethylene-vinylacetate, etc. or their combination. The viscosity of suspension adjuvant is 100 cp-3000 cp, said suspension adjuvant is selected from sodium cellulose glycollate. The slow-released microsphere also can be made into slow-released implant preparation. Said invention also provides its application method for curing various tumors and cancers.
Citrobacter koseri (formerly classified as Citrobacter diversus) is a gram-negative bacillus (GNB) that occurs as an opportunistic pathogen in neonates and immunocompromised patients. Citrobacter species have been implicated in nosocomial settings leading to infections involving the urinary tract, respiratory tract, liver, biliary tract, meninges, and even in rarer conditions-blood stream infection and infective endocarditis (IE). Gram-negative bacilli are responsible for 3% to 4% of all IE cases and have been traditionally associated with intravenous drug users. Patients with non-HACEK (species other than Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, or Kinglella species) GNB IE have poor clinical outcomes with higher rates of in-hospital mortality and complications. The American Heart Association (AHA) and Infectious Diseases Society of America (IDSA) both recommend the use of combination antibiotic therapy with a beta-lactam (penicillins, cephalosporins, or carbapenems) and either an aminoglycoside or fluoroquinolones for 6 weeks (about 1 and a half months) to treat IE due to non-HACEK GNB. Citrobacter koseri is becoming more recognized due to its inherent resistance to ampicillin and emerging drug resistance to beta lactams and aminoglycosides requiring carbapenem therapy. Our case is of a 75-year-old male with no previously reported history of primary or secondary immunodeficiency disorders who developed C koseri blood stream infection. His infectious work-up revealed mitral valve IE and septic cerebral emboli resulting in ischemic infarcts. This case illustrates the importance of recognizing GNB organisms as rising human pathogens in IE cases even without active injection drug use or nosocomial exposure.
Producing solid-state formulations of biologics remains a daunting task despite the prevalent use of lyophilization and spray drying technologies in the biopharmaceutical industry. The challenges include protein stability (temperature stresses), high capital costs, particle design/controllability, shortened processing times and manufacturing considerations (scalability, yield improvements, aseptic operation, etc.). Thus, scientists/engineers are constantly working to improve existing methodologies and exploring novel dehydration/powder-forming technologies. Microglassification™ is a dehydration technology that uses solvent extraction to rapidly dehydrate protein formulations at ambient temperatures, eliminating the temperature stress experienced by biologics in traditional lyophilization and spray drying methods. The process results in microparticles that are spherical, dense, and chemically stable. In this study, we compared the molecular stability of a monoclonal antibody formulation processed by lyophilization to the same formulation processed using Microglassification™. Both powders were placed on stability for 3 months at 40 °C and 6 months at 25 °C. Both dehydration methods showed similar chemical stability, including percent monomer, charge variants, and antigen binding. These results show that Microglassification™ is viable for the production of stable solid-state monoclonal antibody formulations.
New higher N-alkyl sulphonamide derivs. are cpds. of formula (I) R1SO2NR2R3 (where R1 is 1-3C alkyl, phenyl or p-tolyl; R2 is 10-20C alkyl; and R3 is H, 1-3C alkyl or 2-3C hydroxyalkyl). (I) are antimicrobial agents with good bacteriostatic and bactericidal activity, adequate solubility in water, reasonable to very good solubility in organic solvents, and stability over a wide pH range. They are suitable for use as cleansing, disinfectant and preservative agents for textiles, floors, medical instruments, hospital equipment, or installations such as dairies, breweries and laundries. (I) can also be used as preservatives for technical products. Because they are physiologically well tolerated, (I) may be used as antimicrobials in body-care preparations and/or cosmetics. The activity of (I) may be enhanced by combining with complexing agents having a CaCO3-binding capacity greater than 230 mg/g in the Hamshire test.
BACKGROUND: Prolonged standing at work may contribute to increased risk of musculoskeletal pain in home care workers. Patients' activities of daily living (ADL) score may be a proxy for home care workers' standing time at work. The objective of the present study was to investigate the association between patients' ADL self-care score, and workers standing time.
METHODS: This cross-sectional study measured time spent standing, sitting and in physical activity for seven days using thigh-worn accelerometers, among 14 home care workers. Patients' ADL self-care scores are routinely adjusted by home care nurses, and time intervals of home care visits are stored in home care services electronic patient journal. We collected ADL self-care scores and start and end time points of visits, and categorized ADL self-care scores as low (ADL ≤ 2.0), medium (ADL > 2.0 to 3.0) or high (ADL > 3.0). Physical behavior data were transformed to isometric log-ratios and a mixed-effect model was used to investigate differences in physical behavior between the three ADL self-care score categories.
RESULTS: We analyzed 931 patient visits and found that high ADL self-care scores were associated with longer standing times relative to sitting and physical activity, compared to low ADL score (0.457, p = 0.001). However, no significant differences in time spent standing were found between high and medium ADL patient visits (0.259, p = 0.260), nor medium and low (0.204, p = 0.288). High ADL score patients made up 33.4% of the total care time, despite only making up 7.8% of the number of patients.
CONCLUSION: Our findings suggest that caring for patients with high ADL self-care score requires workers to stand for longer durations and that this group of patients constitute a significant proportion of home care workers' total work time. The findings of this study can inform interventions to improve musculoskeletal health among home care workers by appropriate planning of patient visits.
Curative antidote for organophosphours pesticide poisoning contains as active constituents 1-6mg of atropine sulphate, 5-12mg of ethylbenztropine, 100-250mg of obidoxime chloride and 5-15mg of ephedrine. Antidote antagonises the action of organophosphorus pesticides on peripheral and central, cholinergic biochemical systems. They unblock peripheral myoneural structures. A typical compsn. for treating slight or initial stages of poisoning contains 1mg of atropine sulphate, 5mg of ethylbenztropine hydrochloride, 100mg of obidoxime chloride and 5mg of ephedrine in 1.5-2ml for i.m. injection.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are increasingly recognized for their role in reducing the risk and improving the prognosis of heart failure (HF). However, the precise mechanisms involved remain to be fully delineated. Evidence points to their potential anti-inflammatory pathway in mitigating the risk of HF.
METHODS: A two-sample, two-step Mendelian Randomization (MR) approach was employed to assess the correlation between SGLT-2 inhibition and HF, along with the mediating effects of inflammatory biomarkers in this relationship. MR is an analytical methodology that leverages single nucleotide polymorphisms as instrumental variables to infer potential causal inferences between exposures and outcomes within observational data frameworks. Genetic variants correlated with the expression of the SLC5A2 gene and glycated hemoglobin levels (HbA1c) were selected using datasets from the Genotype-Tissue Expression project and the eQTLGen consortium. The Genome-wide association study (GWAS) data for 92 inflammatory biomarkers were obtained from two datasets, which included 14,824 and 575,531 individuals of European ancestry, respectively. GWAS data for HF was derived from a meta-analysis that combined 26 cohorts, including 47,309 HF cases and 930,014 controls. Odds ratios (ORs) and 95% confidence interval (CI) for HF were calculated per 1 unit change of HbA1c.
RESULTS: Genetically predicted SGLT-2 inhibition was associated with a reduced risk of HF (OR 0.42 [95% CI 0.30-0.59], P < 0.0001). Of the 92 inflammatory biomarkers studied, two inflammatory biomarkers (C-X-C motif chemokine ligand 10 [CXCL10] and leukemia inhibitory factor) were associated with both SGLT-2 inhibition and HF. Multivariable MR analysis revealed that CXCL10 was the primary inflammatory cytokine related to HF (MIP = 0.861, MACE = 0.224, FDR-adjusted P = 0.0844). The effect of SGLT-2 inhibition on HF was mediated by CXCL10 by 17.85% of the total effect (95% CI [3.03%-32.68%], P = 0.0183).
CONCLUSIONS: This study provides genetic evidence supporting the anti-inflammatory effects of SGLT-2 inhibitors and their beneficial impact in reducing the risk of HF. CXCL10 emerged as a potential mediator, offering a novel intervention pathway for HF treatment.
BACKGROUND: Low air quality related to ambient air pollution is the largest environmental risk to health worldwide. Interactions between air pollution emissions may affect associations between air pollution exposure and chronic diseases. Therefore, this study aimed to quantify interactions among air pollution emissions and assess their effects on the association between air pollution and diabetes.
METHODS: After constructing long-term emission networks for six air pollutants based on data collected from routine monitoring stations in Northeast China, a mutual information network was used to quantify interactions among air pollution emissions. Multiple linear regression analysis was then used to explore the influence of emission interactions on the association between air pollution exposure and the prevalence of diabetes based on data reported from the Northeast Natural Cohort Study in China.
RESULTS: Complex network analysis detected three major emission sources in Northeast China located in Shenyang and Changchun. The effects of particulate matter (PM2.5 and PM10) and ground-level ozone (O3) emissions were limited to certain communities but could spread to other communities through emissions in Inner Mongolia. Emissions of sulfur dioxide (SO2), nitrogen dioxide (NO2), and carbon monoxide (CO) significantly influenced other communities. These results indicated that air pollutants in different geographic areas can interact directly or indirectly. Adjusting for interactions between emissions changed associations between air pollution emissions and diabetes prevalence, especially for PM2.5, NO2, and CO.
CONCLUSIONS: Complex network analysis is suitable for quantifying interactions among air pollution emissions and suggests that the effects of PM2.5 and NO2 emissions on health outcomes may have been overestimated in previous population studies while those of CO may have been underestimated. Further studies examining associations between air pollution and chronic diseases should consider controlling for the effects of interactions among pollution emissions.
This condition will mirror the MI component of the PP-MI intervention. During the first three sessions, participants will learn about the causes and types of HF, risk factors for cardiovascular disease, and methods for monitoring risk factors and symptoms. Then participants will complete nine sessions related to physical activity, a low sodium diet, and medication adherence. Weekly tasks (e.g., brainstorming barriers) will be assigned, completed between calls, and reviewed at the following call. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure. HNHF-O2 may be beneficial in patients with COPD and chronic impairments in gas exchange, both hypoxemia as well as hypercapnia. HNHF-O2 may decrease work of breathing, reduce dyspnea, improve airway humidification, and potentially stabilize or reduce carbon dioxide levels. However, there is limited data showing the chronic effects of HNHF-O2 in patients with hypercapnic respiratory failure, specifically those discharged to home following hospitalization for an acute exacerbation. Data that demonstrates that HNHF-O2 is well tolerated, and stabilizes or improves gas exchange long term in patients with COPD is lacking. Similarly, data that demonstrates that this therapeutic regimen is feasible to provide to patients in the home environment are lacking. This is an open-labeled pilot study of thirty patients to determine the safety and feasibility of using the device in the outpatient management of patients with COPD. A subset of ten patients will have serial sleep studies to determine the effects, if any, on sleep.
1,157,370. Implantable pellet containers. PHYTOGEN PRODUCTS Inc. 17 Aug., 1967 [23 Aug., 1966], No. 37862/67. Headings A5B and A5R. A surgically implantable medicament pellet container comprises a side wall (12), foraminous to and bottom surfaces 20 (22) and an eye 26 integral with the side wall by means of which the container may be withdrawn from tissue. The side wall is made in two halves separable horizontally or vertically for insertion of the pellet 24. The top and bottom surfaces comprise a wet-like arrangement of interconnected strips 28. The pellet has frustospherical elevations (37) in its top and bottom faces which in use project beyond the side wall of the container and against which the top and bottom surfaces resiliently bear. The pellet comprises an inactive central layer (35) and top and bottom layers (31, 33) containing the active agent 3-ethylene dioxy 17-acetoxy, 6-methyl pregn-5-ene-20-one. Each layer comprises a mixture of cholesterol, Carbo wax and magnesium stearate.
PROBLEM TO BE SOLVED: To dissolve troublesomeness accompanying the medicine name editing work in prescription issuing method and device using a display means having a GUI function. SOLUTION: This device is provided with the display means having the GUI function for displaying prescription contents and a pointing means for pointing items displayed on it and performing free handwriting. The editing work of a prescription is performed by using object buttons and editing buttons together. Menu buttons on the upper stage of a prescription window are constituted of medicine input buttons 4-1, 4-2 and 4-3, the editing buttons 5-1, 5-2 and 5-3, an editing stop button 6 and a prescription issuing button 7. The object buttons 8-1, 8-2, 9-1, 9-2, 9-3 and 9-4 mounted on the left end specify the editing object of the item. Thus, the editing work is performed with absolute minimum operations and line-of-sight movement and a comfortable operation environment is realized.
In Taiwan, non-small cell lung cancer (NSCLC) has been the leading cause of cancer death, making a phenomenal impact on public health. By understanding the oncogenic driver mutations of NSCLC (e.g. EGFR mutation or ALK rearrangement), the target therapy has taken the place of chemotherapy for its effectiveness and specificity, becoming the new standard of care for stage IV NSCLC. Despite the progress of medical treatment, the majority of patients with stage IV NSCLC still underwent disease progression after a period of time. Noticeably, more than half of the progression was restricted to the original sites of the tumor. It brings up the hypothesis that a combination of local consolidative therapy (e.g. surgery or radial therapy) and medical treatment could be beneficial for these patients. This has been advocated by the latest clinical trials as well.

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong the progression-free survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.